Cargando…

A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients

Detalles Bibliográficos
Autores principales:	Wang, Biyun, Zhao, Yannan, Li, Yi, Xu, Yingying, Chen, Yun, Jiang, Qiuyu, Yao, Dingjin, Zhang, Li, Hu, Xichun, Fu, Chaowei, Zhang, Si, Chen, She
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764855/ https://www.ncbi.nlm.nih.gov/pubmed/35042534 http://dx.doi.org/10.1186/s12943-022-01504-0

Ejemplares similares

A three-snoRNA signature: SNORD15A, SNORD35B and SNORD60 as novel biomarker for renal cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2023)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “PET biopsy” method
por: Xie, Yizhao, et al.
Publicado: (2019)

A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple‐negative breast cancer
por: Lin, Mingxi, et al.
Publicado: (2020)

Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis
por: Xie, Yizhao, et al.
Publicado: (2022)

Plasma SNORD42B and SNORD111 as potential biomarkers for early diagnosis of non‐small cell lung cancer
por: Wang, Kangyu, et al.
Publicado: (2022)

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

SNORD63 and SNORD96A as the non-invasive diagnostic biomarkers for clear cell renal cell carcinoma
por: Shang, Xiaoling, et al.
Publicado: (2021)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li, Yi, et al.
Publicado: (2020)

Phylogenetic Analysis of the SNORD116 Locus
por: Kocher, Matthew A., et al.
Publicado: (2017)

Immunoglobulin superfamily 9 (IGSF9) is trans-activated by p53, inhibits breast cancer metastasis via FAK
por: Li, Yaohua, et al.
Publicado: (2022)

Heterogeneity derived from (18)F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients
por: Xie, Yizhao, et al.
Publicado: (2022)

Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial
por: Zhao, Yannan, et al.
Publicado: (2018)

Snord116 is critical in the regulation of food intake and body weight
por: Qi, Yue, et al.
Publicado: (2016)

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
por: Gong, Chengcheng, et al.
Publicado: (2017)

Antisense pairing and SNORD13 structure guide RNA cytidine acetylation
por: Thalalla Gamage, Supuni, et al.
Publicado: (2022)

SNORD76, a box C/D snoRNA, acts as a tumor suppressor in glioblastoma
por: Chen, Luyue, et al.
Publicado: (2015)

SNORD90 induces glutamatergic signaling following treatment with monoaminergic antidepressants
por: Lin, Rixing, et al.
Publicado: (2023)

An SNP reducing SNORD105 and PPAN expression decreases the risk of hepatocellular carcinoma in a Chinese population
por: Chen, Xuekun, et al.
Publicado: (2021)

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
por: Hu, Xichun, et al.
Publicado: (2014)

Dietary Conjugated Linoleic Acid Reduces Body Weight and Fat in Snord116(m+/p−) and Snord116(m−/p−) Mouse Models of Prader–Willi Syndrome
por: Knott, Brittney, et al.
Publicado: (2022)

Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer
por: Cao, Jun, et al.
Publicado: (2022)

Identification of Small Nucleolar RNA SNORD60 as a Potential Biomarker and Its Clinical Significance in Lung Adenocarcinoma
por: Zhou, Hongwei, et al.
Publicado: (2022)

SNORD6 promotes cervical cancer progression by accelerating E6-mediated p53 degradation
por: Li, Qianhui, et al.
Publicado: (2023)

The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53
por: Su, Xi, et al.
Publicado: (2021)

Mutations in SNORD118 cause the cerebral microangiopathy leukoencephalopathy with calcifications and cysts
por: Jenkinson, Emma M., et al.
Publicado: (2016)

Hypothalamic loss of Snord116 recapitulates the hyperphagia of Prader-Willi syndrome
por: Polex-Wolf, Joseph, et al.
Publicado: (2018)

Snord116-dependent diurnal rhythm of DNA methylation in mouse cortex
por: Coulson, Rochelle L., et al.
Publicado: (2018)

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer
por: Chen, Yimeng, et al.
Publicado: (2023)

Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

LncRNA-LALR1 upregulates small nucleolar RNA SNORD72 to promote growth and invasion of hepatocellular carcinoma
por: Mao, Lin-Hong, et al.
Publicado: (2020)

A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer
por: Wang, Biyun, et al.
Publicado: (2022)

An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy
por: Qi, Lishuang, et al.
Publicado: (2016)

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data
por: Gong, Chengcheng, et al.
Publicado: (2022)

Revealing the clinical significance and prognostic value of small nucleolar RNA SNORD31 in hepatocellular carcinoma
por: Ding, Yuan, et al.
Publicado: (2020)

The SNORD115 (H/MBII-52) and SNORD116 (H/MBII-85) gene clusters at the imprinted Prader–Willi locus generate canonical box C/D snoRNAs
por: Bortolin-Cavaillé, Marie-Line, et al.
Publicado: (2012)

Snord 3A: A Molecular Marker and Modulator of Prion Disease Progression
por: Cohen, Eran, et al.
Publicado: (2013)

RNA-Seq of the Nucleolus Reveals Abundant SNORD44-Derived Small RNAs
por: Bai, Baoyan, et al.
Publicado: (2014)

Immunotherapy vs platinum for advanced or metastatic thymic carcinoma: A protocol for systematic review and meta analysis
por: Qian, Jiekun, et al.
Publicado: (2021)

Overexpression of small nucleolar RNA SNORD1C is associated with unfavorable outcome in colorectal cancer
por: Liu, Yonghui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_013lv5b5b56frtm83k3msii6go